期刊文献+

CD34在膀胱移行细胞癌中的表达及MVD的临床意义 被引量:2

Expressions of CD34 and the MVD in transitional cell carcinoma of the bladder
下载PDF
导出
摘要 目的检测CD34在膀胱移行细胞癌组织中的表达及微血管密度(MVD),探讨其在膀胱移行细胞癌发生、发展、浸润和转移中的作用及相互关系。方法采用免疫组织化学SP法。结果CD34蛋白在膀胱移行细胞癌无淋巴结转移组和淋巴结转移组中的阳性表达率分别为55.00%和40.00%,MVD值分别为26±6,24±5。两组间CD34蛋白阳性表达率及MVD值分别比较,差异均有统计学意义(P<0.05)。无明显浸润组和浸润组中CD34蛋白的阳性表达率分别为:57.89%和35.29%,MVD值分别为29±5,25±7。两组间CD34蛋白阳性表达率及MVD值分别比较,差异均有统计学意义(P<0.05)。结论CD34蛋白阳性表达及MVD值的高低与膀胱移行细胞癌发生、发展、浸润和转移有关。 Objective To detect the expression of CD34 and MVD and discuss their con'elation of the pathogenesis,development, invasion and metastasis in transitional cell carcinoma of the bladder tissues. Methods By adopting immunohistochemisty SP method. Results In the groups of non - lymphaden metastasis and lymphaden metastasis, the positive rates of CD34 protein were 55.00% (11/20 ) and 40.00% (4/10)respectively and the MDV were 26 ± 6 and 24 ± 5 respectively. The difference of them in the two groups had statistical significance( P 〈 0.05 ). In the groups of non - invasion and invasion, the positive at of CD34 protein were 57.89% (11/19) and 35.29% (6/17) respectively and the MDV were 29 ± 5 and 25 ± 7 respectively. The difference of them in the two groups had statistical significance ( P 〈 0.05 ). Conclusion The positive expression of CD34 and MVD were correlated with pathogenesis,development, invasion and metastasis of transitional cell carcinoma of the bladder.
出处 《中原医刊》 2006年第6期6-9,共4页 Central Plains Medical Journal
关键词 膀胱移行细胞癌 CD34 MVD 转移 Transitional cell carcinoma of the bladder CD34 MVD Metastasis
  • 相关文献

参考文献14

  • 1Folkman J. Tumor angiogenesis : therapeutic implications. N Engl J Med,1971,285 : 1182 -1186.
  • 2Li C, Guo B, Bernabeu C, et al. Angiogenesis in breast cancer: the transforming growth factor beta and CD105. Microsc Res Tech,2001,52(4) :437 - 449.
  • 3Brewer CA, Setterdah JJ, Li MJ, et al, Endoglin expression as a measure of microvessel density in cervical cancer. Obstet Gynecol, 2000,96 (2) :224 - 228.
  • 4Weider N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat, 1995,36 ( 2 ) : 169.
  • 5Folkman J. What is the evidence that tumors are antigenesis dependent?J Natl Cancer Inst,1990,82( 1 ) :4 -6.
  • 6李丙华,徐娅苹,陈鸣,彭佳萍.CD_(105)与CD_(34)在喉癌微血管中的表达及临床意义[J].浙江预防医学,2004,16(6):18-19. 被引量:6
  • 7Ehrmann R, Knoth M. Choriocarcinoma : transfllter stimulation of vasoproliferation in the hamster cheek pouch studied by light and electron microscopy. J Natl Cancer Inst, 1968,41 : 1329 - 1341.
  • 8Yamamoto A, Dhar DK, EI Assl ON, et al. Thymidine phosphorylase(platelet- derived endothelial cell growth factor), microvessel density and dinical outcome in hepatorcellular carcinoma. J Hepatol, 1998,29:290-299.
  • 9Sugawara Y, Makuuchi M, Harihara Y,et al. Tumor angiogenesis in gallbladder carcinoma. Hepatofastroenterology, 1999,46 ( 27 ) : 1682 - 1686.
  • 10Hamahan D, Folkman J. Patterns and emerging mechanisms of angiogenesis switch during tumorgenesis. Cell, 1997,86:354 - 364.

二级参考文献6

  • 1Cox G, Jones JL, Walker RA, et al. Angiogenesis and non - small cell lung cancer [J]. Lung Cancer, 2000, 27 (2): 81 ~ 100.
  • 2Holmgren L, O'Reilly MS, Folkman J, et al. Dormancy of micrometastasis: balanced proliferation and apoptosis in the angiogenesis suppression [J]. Nat Med, 1995, 1 (2): 149~153.
  • 3Murray JD, Carlson GW, Mclaughlin K, et al. Tumor angiogenesis as a prognostic significance in iaryngeal cancer [J]. Am J Surg, 1997,174 (5): 523 ~ 526.
  • 4Hagedorn HG, Nerlich AG. Microvessel density and endothelial basement membrane composition in laryngeal squamous cell carcinoma.Acta Otolaryngol, 2000, 120 (7): 891 ~ 898.
  • 5Brewer CA, Setterdahl JJ, Li MJ, et al. Endoglin expression as a measure of microvessel density in cervical cancer [J]. Obstet Gynecol,2000, 96 (2): 224~228.
  • 6Kumar S, Ghellal A, Li C, et al. Breast Carcinoma: Vasular density detemined using CD105 antibody correlates with tumor prognosis [J].Cancer Res, 1999, 59 (4): 856 ~ 861.

共引文献5

同被引文献37

  • 1Tumer HE, Nagy Z, Esiri MM, et al. Role of matrix metalloproteinase 9 in pituitary tumor behavior[J].J Clin Endocrinol Metab, 2000,85(8) : 2931 -2935.
  • 2Li C, Guo B, Bemabeu C, et al. Angiogenesis in breast cancer: the transforming growth factor beta and CD105[J]. Microsc Res Tech, 2001,52(4) :437 -449.
  • 3Farias E, Ranuncolo S, Creta C, et al. Plasua metaUproteinase activity is enhanced in theeuglobulin fraction of breast and lung cancer patients[J]. Int J Cancer, 2000,89:389 -394.
  • 4Visse R,Nagase H. Matrix metaUoproteinases and tissue inhibitors of metalloproteinases : structure, function, and biochemistry [ J ]. Circ Res ,2003,92:827 - 839.
  • 5Nielsen BS. Expression of matrix metalloproteinase - 9 in vascular pericytes in human breast cancer[ J ]. Lab Invest, 1997,77:345 - 355.
  • 6Celentano DC, Frishman WH. Matrix metalloproteinases and coronary disease: a novel therapeutic target [ J ]. J Clin Pharmacol, 1997,137(11) :991 - 1000.
  • 7Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy [J]. J Natl Cancer Inst,2001,93(3) : 178 - 193.
  • 8Lioffa. Isolation of a protein that stimulates blood vessel growth[J].Nature,1985,318 (6041): 14.
  • 9Powell WC, Knox JD, Navre M, et al. Expression of the metalloproteinases matrilysis in Dn - 145 cells increases their invasive potential in severe combined immunodeficient mice [ J ]. Cancer Res,1993, 53:417 -422.
  • 10Nuttall RK, Penning, ton CJ, Taplin J, et al. Elevated membrane type metrix metal - loproteinases in gliomas revealed by profiling proteasea and inhibitor in human cancer cell[J].Mol Cancer Res, 2003,1(5): 333-345.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部